Webinar Overview
With antibodies serving as critical intermediates in ADCs, antibody development constitutes a major part of ADC projects. The ability to achieve efficient antibody development and robust large-scale production has become a key determinant in accelerating the overall ADC development timeline.
The session will discuss efficient upstream cell culture process development, robust scale-up, and process characterization in ADC programs, supported by practical case studies from AsymBio’s Upstream Process Development Platform. The presentation will illustrate how optimizing key process parameters can enhance intermediate quality and yield, supporting the transition from early-stage development through to commercial production.
Key Learning Objectives:
· Understand key considerations for efficient upstream cell culture process development
· Gain insight into scaling processes from laboratory to production scale
· Learn approaches for process characterization to ensure reproducibility and product quality
Speaker:
Zhenshou Wang
Director of Cell Culture Process Development Department, AsymBio
AsymBio is committed to becoming a technology-driven, fully-empowered one-stop CDMO services platform for biologics offering customized services with outstanding quality and efficient performance. We provide comprehensive, customized one-stop services for antibodies, recombinant biotherapeutics, bioconjugates, plasmids, and mRNAs, which including but not limited to development, manufacturing, quality control and regulatory affairs.